TP63 and colorectal carcinoma: Regarding the discrimination between CRC patients from healthy individuals, the differential seroreactivity to p53 and p63 proteoforms showed individual AUCs up to 80.1% and 74.7%, with specificity up to 75% and 89.6%, and sensitivity up to 93.55% and 80.6%.